更新于：2024-11-01

Small Cell Carcinoma

小细胞癌

更新于：2024-11-01

基本信息

别名

Carcinoma, Oat Cell、Carcinoma, Small Cell、Carcinomas, Oat Cell

+ [40]

简介

An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)

关联

项与小细胞癌相关的药物

Tremelimumab

曲美木单抗

靶点

CTLA4

作用机制

CTLA4抑制剂

在研机构

AstraZeneca PLC [+12]

原研机构

AstraZeneca AB [+1]

在研适应症

肝细胞癌 [+59]

非在研适应症

晚期癌症 [+50]

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2022-10-21

Apalutamide

阿帕他胺

靶点

作用机制

AR拮抗剂

在研机构

Janssen Pharmaceutica NV [+11]

原研机构

Janssen Global Services LLC

在研适应症

转移性去势抵抗性前列腺癌 [+13]

非在研适应症

阿尔茨海默症 [+2]

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2018-02-14

Niraparib Tosylate

甲苯磺酸尼拉帕利

靶点

PARP1 x PARP2

作用机制

PARP1抑制剂 [+1]

在研机构

Janssen Research & Development LLC [+14]

原研机构

Merck Sharp & Dohme Corp.

在研适应症

BRCA 突变卵巢癌 [+78]

非在研适应症

晚期胆管癌 [+29]

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2017-03-27

118

项与小细胞癌相关的临床试验

NCT06161532 / Recruiting临床2期IIT

A Phase II Study of Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as Small Cell, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile Cancer

Background:
Rare tumors of the genitourinary (GU) tract can appear in the kidney, bladder, ureters, and penis. Rare tumors are difficult to study because there are not enough people to conduct large trials for new treatments. Two drugs-sacituzumab govitecan (SG) and atezolizumab-are each approved to treat other cancers. Researchers want to find out if the two drugs used together can help people with GU.
Objective:
To test SG, either alone or combined with atezolizumab, in people with rare GU tumors.
Eligibility:
Adults aged 18 years and older with rare GU tumors. These may include small cell carcinoma of the bladder; squamous cell carcinoma of the bladder; primary adenocarcinoma of the bladder; renal medullary carcinoma; or squamous cell carcinoma of the penis.
Design:
Participants will be screened. They will have a physical exam with blood and urine tests. They will have tests of heart function. They will have imaging scans. They may need a biopsy: A small needle will be used to remove a sample of tissue from the tumor.
Both SG and atezolizumab are given through a tube attached to a needle inserted into a vein in the arm.
All participants will receive SG on days 1 and 8 of each 21-day treatment cycle. Some participants will also receive atezolizumab on day 1 of each cycle.
Blood and urine tests, imaging scans, and other exams will be repeated during study visits.
Treatment may continue for up to 5 years.
Follow-up visits will continue for 5 more years.

开始日期2024-08-01

申办/合作机构

National Cancer Institute

NCT06478264 / Not yet recruiting临床2期IIT

Efficacy and Safety of Adebrelimab Combined With Chemoradiotherapy in the Treatment of Esophageal Small Cell Carcinoma: a Single-arm, Multicenter, Phase II Clinical Study

To evaluate the efficacy and safety of adebrelimab combined with chemoradiotherapy in the treatment of esophageal small cell carcinoma

开始日期2024-07-13

申办/合作机构-

NCT06228066 / Recruiting临床2期IIT

A Phase II Study of Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)

Background:
Small cell carcinoma of the bladder (SCCB) and other high-grade neuroendocrine tumors (HGNET) of the urinary tract are rare but aggressive cancers. Average survival for people diagnosed with SCCB or HGNET is about 1 year. Lurbinectedin and avelumab are drugs that are approved to treat other cancers. Researchers want to see if these drugs can help people with SCCB or HGNET.
Objective:
To test lurbinectedin with or without avelumab in people with SCCB or HGNET.
Eligibility:
Adults aged 18 years and older with SCBB or HGNET that returned and spread after treatment.
Design:
Participants will be screened. They will have a physical exam. They will have blood tests and imaging scans. They may need to have a new biopsy: A small needle will be used to collect a tissue sample from the tumor.
Both study drugs are given through a tube attached to a needle inserted into a vein. If participants have already received a drug like avelumab they will receive only lurbinectedin. If patients have not been previously treated with a drug like avelumab they will receive both lurbinectedin and avelumab. All participants will receive their treatment once every 3 weeks for up to 10 years. They will also receive other drugs to relieve adverse effects.
Biopsies, blood tests, and imaging scans will be repeated during some study visits. Participants may also have urine tests and tests of their heart function.
Participants may remain in the study as long as the treatment is helping them. If they stop treatment, they will have safety visits 14, 30, and 90 days after their last dose. Additional follow-up visits will continue 5 to 10 years.

开始日期2024-06-13

申办/合作机构

National Cancer Institute

100 项与小细胞癌相关的临床结果

登录后查看更多信息

100 项与小细胞癌相关的转化医学

登录后查看更多信息

0 项与小细胞癌相关的专利（医药）

登录后查看更多信息

7,894

项与小细胞癌相关的文献（医药）

2025-01-01·Modern Pathology

POU4F3 Is a Sensitive and Specific Marker of Merkel Cell Carcinoma

Article

作者: Karpinski, Paweł ; Hung, Yin P. ; Hung, Yin P ; Cornejo, Kristine M. ; Wu, Cheng-Lin ; Mendez-Pena, Javier E ; Cornejo, Kristine M ; Mendez-Pena, Javier E. ; Karpinski, Pawel ; Hoang, Mai P. ; Akalin, Ali ; Hoang, Mai P

Although of therapeutic importance, a single sensitive and specific immunostain to distinguish Merkel cell carcinoma (MCC) from mimics is not currently available. In addition, single tumor cells are difficult to detect in sentinel lymph node biopsy. Leveraging publicly available data sets of 9264 solid tumors and >600,000 single-cell transcriptomes, we identified POU4F3 to be a specific marker of MCC. Analyses of Pan-Cancer RNA bulk sequencing data of 24 tumor types from Tumor Cancer Genomic Atlas data sets as well as non-Tumor Cancer Genomic Atlas small cell lung carcinoma and MCC data sets confirmed POU4F3 specificity for MCC. Single-cell RNA-sequencing analyses also confirmed the lack of POU4F3 expression in lung small cell carcinoma as well as a variety of normal tissues. Nuclear POU4F3 immunohistochemical expression was noted in 98.7% of 153 MCCs and in only 1.7% of mimics (3 of 180 cases, including 95 small cell carcinomas, of which 55 were from lungs and the remainder from other sites). Three POU4F3-positive non-MCC cases were from lungs (2 cases) and vagina (1 case). All 153 tested MCC cases were negative for ASCL1, a key transcriptional regulator highly expressed in small cell lung carcinoma. NeuroD1 was seen in a subset of MCC cases (20.9%, 32/153). POU4F3 immunostain was performed on 29 sentinel lymph nodes, and strong POU4F3 nuclear expression facilitated the ease of metastasis detection, even single tumor cells. Our study built on prior works shows that POU4F3 is a sensitive and specific clinical marker of MCC.

2024-12-01·Clinical Genitourinary Cancer

Prognostic Nomogram, Demographics and Comparative Analysis of Urinary Bladder Small Cell and Large Cell Neuroendocrine Carcinoma

Article

作者: Yasinzai, Abdul Qahar Khan ; Tareen, Bisma ; Ullah, Asad ; Karki, Nabin Raj ; Chaudhury, Hannah ; Arif, Dauod ; Khan, Marjan ; Chaudhury, Tristin ; Chandasir, Abdullah ; Karki, Nabin R ; Waheed, Abdul ; Brandi, Luis ; Wali, Agha ; Sharma, Meenu ; Iqbal, Asif ; Karki, Nabin R. ; Jamil, Nimra ; Lee, Kue Tylor

BACKGROUNDThis retrospective study aims to provide a comprehensive analysis of the demographics, survival rates, and therapeutic approaches of small-cell neuroendocrine carcinoma (SCNEC) and large-cell neuroendocrine carcinoma (LCNEC) while highlighting key differences compared to common urinary bladder cancers.METHODSOur analysis utilized the Surveillance, Epidemiology, and End Results database (SEER), and data was collected from 2000-2020.RESULTSA total of 1040 cases of urinary bladder SCNEC and LCNEC were identified. Most patients were over the age of 80 years (33.2%), male (78.9%), and Caucasian (83.6%). Most tumors were over 4.1cm (47.4%) and in the lateral wall of the bladder (37.8%). The overall 5-year survival was 22.1% (95% confidence interval (95% CI):20.7-23.5). The 5-year survival by sex was greatest for the female population (28.0%; (95% CI: 24.5-35.0). For treatment modality, the 5-year survival for each was as follows: surgery, 12.5% (95% CI: 10.5-14.5) multimodality therapy (surgery and chemotherapy), 31.1% (95% CI: 28.5-33.7) and combination (surgery, chemotherapy, and radiation) 32.8% (95% CI: 29.1-36.5). On multivariable analysis, positive nodal status hazar ratio (HR)(HR3.65 [95% CI: 2.34-5.71], P < .001) was identified as a negative predictor for survival, and increasing age was nearly significant for a worse prognosis (P = .052). The prognostic nomogram that was created to predict patient survivability mirrored the findings from the statistical analysis, with a statistically significant difference found in race, treatment modality, and tumor stage.CONCLUSIONSSCNEC and LCNEC are rare yet highly intrusive subtypes of bladder cancer that usually affect Caucasian males over the age of 80 years old. The study identifies older age and positive nodal status as adverse prognostic indicators. Our findings offer crucial insights that can inform future clinical guidelines and serve as a basis for more tailored treatment strategies for these aggressive subtypes of bladder cancer.

2024-12-01·Radiology Case Reports

First reported case of primary small cell cancer of the pancreas with positive TTF-1 tumor marker

Article

作者: Merza, Nooraldin ; Hashim, Hashim Talib ; Al-Obaidi, Ahmed Dheyaa ; Al-Badri, Sajjad Ghanim ; Agha, Iya ; Al-Obaidi, Hasan ; Mora, Maximo ; Harb, Hussein ; Moliya, Pratiksha ; Othman, Assalah ; Patel, Avani

Small cell carcinomas are very aggressive malignancies that are most often linked with lung cancer, although they may also develop in the pancreas, colon, rectum, skin, and cervix. SCC of the pancreas accounts for about 1% of these neoplasms. An 88-year-old male with several comorbidities who presented with significant weight loss was diagnosed with metastatic pancreatic neuroendocrine carcinoma after complaining of persistent epistaxis and back pain. This case underscores the significance of using atypical tumor markers, such as thyroid transcription factor 1, to diagnose small-cell pancreatic cancer. It also emphasizes the importance of a multidisciplinary, patient-centered approach to managing these aggressive tumors.

386

项与小细胞癌相关的新闻（医药）

2024-10-18

·研发客

宜联生物任命Bruce Chabner博士为资深战略顾问，以增强其全球临床开发实力 | 新闻稿

中国苏州、美国马萨诸塞州剑桥，2024年10月18日——苏州宜联生物医药有限公司（以下简称“宜联生物”），一家处于临床阶段的生物科技公司，今日宣布任命Bruce A. Chabner医学博士为资深战略顾问。Chabner博士在肿瘤医学方面的丰富专业知识将帮助宜联生物加强其下一代抗体偶联药物（ADC）管线的全球研发。 “非常荣幸欢迎Bruce Chabner博士的加入，”宜联生物首席执行官薛彤彤博士说，“Bruce是当今世界上最有经验的肿瘤医学家之一，他有着多年的丰富经验以及深刻的科学视野。Chabner博士的加入将帮助宜联的ADC管线推进至新的高度。这对宜联来说非常重要，因为我们的创新ADC管线正处于推向全球病患的关键时刻。” Bruce A. Chabner博士是美国麻省总医院（Massachusetts General Hospital，MGH）癌症中心名誉临床主任、哈佛医学院教授。他毕业于耶鲁学院和哈佛医学院，曾在国家癌症研究所（National Cancer Institute，NCI）Vincent De Vita的指导下接受医学肿瘤学训练，并在耶鲁大学Joseph Bertino的生化药理学实验室进行研究。之后他于1971年回到NCI，1975年成为临床肿瘤学科主任，并从1982年到1995年担任NCI癌症治疗部门主任。在此期间，他负责了紫杉醇、顺铂等多款肿瘤药物的开发。1995年，他加入MGH并担任血液学和医学肿瘤学部门主任以及MGH癌症中心主任。在MGH任职的12年期间，他建立起了对非小细胞癌症等实体瘤的靶向药物开发起到关键作用的相关教职和研究项目。他是2000年成立的Dana Farber/哈佛癌症中心基金的创始科学委员之一，并自此牵头参与其治疗开发项目。他在过去的40年内牵头了多项肿瘤医学项目，并培养出了多位转化和临床医学研究学者。关于宜联生物宜联生物成立于2020年，是一家专注于开发创新型偶联药物的临床阶段生物科技公司。公司开发的新一代具有自主知识产权的肿瘤微环境可激活的新型毒素连接子平台技术（TMALIN®）可实现高DAR值高均一性的稳定偶联，有助于提高ADC药物在实体瘤适应症上的治疗窗。公司致力于以未满足的临床需求为目标，为全球肿瘤患者带来更好的治疗方案。宜联生物位于中国苏州，并在中国上海、美国波士顿建立研发分支机构。

抗体药物偶联物高管变更

2024-08-25

·同写意

小细胞肺癌治疗进入突破加速期

本次大会的主题为“砥砺深耕·笃行致远”，热情邀请全国相关领域专家、学者、科研骨干、企业代表与会交流。在肿瘤领域，任何一项突破都来自不易。尽管人类早已发现了癌症，但长期以来化疗都是核心的治疗手段。当然，经过无数次的失败、希望落空后，一旦有所突破，进展往往也会出人意料。例如，持续数十年的沉寂之后，小细胞癌的的治疗，似乎迎来了加速突破的时期。 8月15日，阿斯利康宣布，其药物度伐利尤单抗针对局限性小细胞肺癌（LS-SCLC）的适应症上市申请已获得FDA的受理。如果获批上市，这将是40年来，首个在该领域显示出生存益处的免疫疗法，代表着重要的突破。对于局限期SCLC，目前的首选一线治疗方法仍然是放化疗，尤其是顺铂联合依托泊苷的治疗方案，这一组合在治疗中占据着绝对主导地位。同样在小细胞肺癌领域取得进展的还有安进，其开发的DLL3/CD3双特异性抗体Tarlatamab于今年5月16日获得批准，为广泛期小细胞肺癌（ES-SCLC）患者提供了新的治疗选择。尽管小细胞肺癌在所有肺癌病例中所占比例不高，但它是最具侵袭性的肺癌亚型之一，患者迫切需要新的治疗手段。期待更多的药企能在这一领域继续取得突破，为患者带来希望。在这个过程中，国内药企也不会缺席。 1 50年的等待对于小细胞癌，医学界的斗争时间已经不短。约在100年前，SCLC被首次发现，并在1968年发现其神经内分泌起源且与其他肺癌有明确区分； 1973年，有研究发现小细胞肺癌早期就具备转移性，是一种进展很快的恶性肿瘤，使得手术治疗的获益较小。根据疾病发展阶段，小细胞肺癌可以分成局限期（LS-SCLC）和广泛期（ES-SCLC）两个阶段，分别约占到小细胞肺癌的1/3和2/3。仅有少数LS-SCLC患者可以通过手术切除获益（约占SCLC人数的5%），对于绝大多数LS-SCLC患者，标准治疗为同步放化疗（cCRT）或序贯放化疗（sCRT）。 80年代，研究表明含铂化疗联合胸部放疗可以提升患者的生存期，这也成为了SCLC的基础疗法。直到现在，依托泊苷和卡铂/顺铂（EP）的组合一直是SCLC的标准治疗。然而，对于SCLC患者来说，只有化疗组合，是远远不够的。核心原因在于，小细胞肺癌对于初始的放化疗非常敏感，但容易产生耐药，大部分患者最终会因疾病复发而死亡。局限期SCLC患者的预后通常较差，诊断后的5年存活率仅为15%至30%。虽然小细胞肺癌只占肺癌的15%左右，但由于肺癌患者规模过于庞大，这部分患者的数量也并不烧。每年在中国有约16万新发小细胞肺癌患者，在美国约有3.3万新发患者。在这一背景下，市场亟需更为有效的疗法，患者已经等待了50年之久。 2 PD-(L)1站了出来率先站出来的，是PD-(L)1。小细胞癌迟迟没有新突破，受到了诸多因素的限制。例如，异质性过于强影响了药物的开发。不过，在药企持续的研发攻坚之下，万金油PD-(L)1带来了不错的效果。第一个突围的是罗氏，阿替利珠单抗开展的IMpower133研究率先攻克了广泛期SCLC。 IMpower133研究是一项全球多中心ph1/3研究，旨在评价阿替利珠单抗联合依托泊苷+卡铂（EC）化疗在广泛期SCLC一线治疗的疗效和安全性。中位随访13.9个月后，研究达到主要终点：与标准化疗相比，阿替利珠单抗联合化疗的中位OS延长了2个月（12.3 vs 10.3个月，HR=0.70，95% CI：0.54-0.91）。凭借IMpower133的关键临床，FDA于2019年3月批准阿替利珠单抗ES-SCLC 1L适应症，这也是首个获批此适应症的免疫疗法。随后，阿斯利康也在该领域成功突围。阿斯利康的CASPIAN研究，共纳入了805例广泛期SCLC患者。度伐利尤单抗+EP组的中位OS为12.9个月，较EP组的10.5个月具有显著生存优势（HR=0.75，p=0.0032）。凭借此数据，度伐利尤单抗同样获批ES-SCLC 1L适应症。除了成功突围广泛期SCLC，正如上文所说，PD-L1在局限性SCLC也将迎来突破。临床数据显示，度伐利尤单抗为局限性SCLC患者带来了不错的治疗选择。对于接受了标准治疗（即同步放化疗）且未出现疾病进展的局限期SCLC患者，与安慰剂相比，度伐利尤单抗能够将死亡风险降低27%；使用该药物的患者的中位总生存期（OS）为55.9个月，而安慰剂组的中位OS为33.4个月。阿斯利康报告称，接受度伐利尤单抗治疗的患者3年后的存活比例为57%。当然，在广泛期SCLC领域，EP联合免疫治疗（PD-1/PD-L1单抗）之后，OS的提升约在2~3个月之间，也只能小幅提升ORR；而在局限性SCLC，度伐利尤的临床并不完美，存在一定程度上的争议。正因此，SCLC领域还需要更多的突围者。 3 吹响战斗号角随着新靶点，新技术的涌现，SCLC的加速突破，是可以期待的。例如，双抗就撕开了一道口子。今年5月16日，安进的DLL3/CD3双抗tarlatamab获FDA加速批准，用于治疗SCLC 2L+患者，打破了该领域只有PD-L1新机制药物的窘境。 Tarlatamab的获批是基于其突出的疗效数据，经治SCLC患者对于tarlatamab有持续的响应和显著的生存获益。具体来看，对于三线以上的SCLC患者，tarlatamab（10mg/100mg）的ORR分别为40%和32%，其中CR分别为1%和8%，DCR分别为70%和62.5%；10mg组的mDOR=9.7 mo，6mo DOR rate=68%，12mo DOR rate=40%。另外，tarlatamab（10mg/100mg）分别取得了4.9/3.9 mo的mPFS，和14.3/NE mo的mOS，对比后线治疗的历史生存数据有十分显著的提升。正是凭借在临床中对三线以上SCLC患者的优秀数据，tarlatamab成功突围。目前，tarlatamab在小细胞癌领域的期待，不只是作为末线疗法，其同时开展了二线、一线疗法的头对头实验。如果最终tarlatamab拿出惊艳的结果，无疑可以覆盖更多前线的SCLC患者。不仅是双抗，包括ADC、CAR-T疗法，也在跃跃欲试。随着临床的推进，其中也必然会出现突围者。例如，在ADC领域，第一三共的I-DXd在后线SCLC患者中展现出有效性。试验对于接受≥6.4mg/kg I-DXd治疗的患者进行了有效性分析（n=21），在mFU=11.7 mo时，cORR=52.4%（11/21），其中CR=4.8%（1/21），mDOR=5.9 mo，几乎所有患者接受治疗后都出现了肿瘤缩小；患者的mPFS=5.6 mo，mOS=12.2 mo。并且，回顾性分析表明，患者的B7-H3表达量与I-DXd的有效性没有明确的相关性，意味着该药物具有广泛的覆盖性。 2023年10月，默沙东以40亿美元首付款、后续24个月内支付15亿美元，以及最高可达165亿美元的销售里程碑的价格，与第一三共就三款ADC达成了权益合作。促成这笔交易的管线之一，就是I-DXd。当然，在这一领域，国内企业也不会缺席。例如，去年11月，传奇生物与诺华就DLL3 CAR-T疗法达成了11亿美元的合作。随着SCLC战斗号角的吹响，期待未来国内更多选手，抓住机会。同写意媒体矩阵，欢迎关注↓↓↓

免疫疗法临床结果加速审批

2024-08-24

·恒瑞医药

食管癌患者关爱日︱“如鲠在喉”？一起来认识食管癌

关于食管癌食管癌是指食管鳞状上皮或腺上皮异常增生所形成的恶性病变，发生于食管粘膜上皮。我国食管癌组织学类型绝大多数为鳞状细胞癌（简称“鳞癌”），约占95%，其余为腺癌、小细胞癌等。中国是食管癌高发国，2020 年全球有超过 60 万例的新发食管癌，其中53.7%的新发食管癌病例和55.3%的食管癌死亡病例发生在中国。统计数据显示，我国食管癌高发区主要集中在太行山脉附近（河南、河北、山西以及山东泰安、济宁和菏泽），及安徽、江苏苏北地区，四川南充、盐亭，广东汕头、福建闽南等地。已知其发病与饮食生活习惯密切相关，包括烫食、热茶、饮酒、吸烟、缺乏蔬菜水果摄入等，此外还包括食品霉变、炭烤或腌制烟熏制备方式、饮用水等因素。食管癌的临床症状多样早期可能仅表现为 ①吞咽粗硬食物时的异物感或梗噎感 ②胸骨后烧灼样或针刺样疼痛 ③食欲缺乏、嗳气、反酸、呕吐、黑便等随着病情的发展，患者可能会出现： ①吞咽困难进行性加重，甚至水和唾液也无法咽下 ②胸痛、咳嗽、发热等提示恶性食管穿孔可能 ③声音嘶哑、饮水呛咳提示喉返神经受侵犯 ④同时还可能伴有消瘦、脱水、无力等症状不明原因出现以上症状的一种，持续一个月仍然未能改善者，一定要及时到正规医院就诊检查。食管癌常见治疗手段手术治疗：将肿瘤及其周围可能受累的组织一并切除，以达到根治的目的放射治疗：利用高能射线杀灭或抑制癌细胞的生长的疗法化学治疗：通过使用抗癌药物来杀灭或抑制癌细胞的生长和扩散靶向治疗：通过针对食管癌细胞上特定的分子靶点，选择性地攻击癌细胞，减少对正常细胞的伤害免疫治疗：免疫点检查抑制剂治疗，即PD-1/PD-L1的治疗，可通过激活免疫系统来阻止癌细胞逃跑、从而更好的识别和杀灭癌细胞我国食管癌患者大约只有一半能在早期被确诊，较为适合根治性手术切除；在局部晚期被确诊的患者，还可接受根治性放化疗；晚期转移性患者的选择就只剩下系统性药物治疗了，其中最重要的是免疫治疗手段1-3。作为创新型国际化制药企业，恒瑞医药多年来在食管癌治疗领域持续展开技术攻关，目前，公司自主研发的人源化PD-1单克隆抗体晚期食管癌一线、二线适应症已经获批上市，且均已纳入国家医保目录。 2024年美国临床肿瘤学会（ASCO）年会上，ESCORT-1st研究结果显示，在全人群中，与化疗组相比公司PD-1抑制剂联合化疗组一线治疗晚期食管鳞癌（ESCC）的中位总生存期（OS）和研究者评估的中位无进展生存期（PFS）均显著获益，且生存曲线差异呈增大趋势，提示公司PD-1抑制剂联合化疗带来“长尾”持久改善。相比化疗组，公司PD-1抑制剂联合化疗组的3年OS率翻倍（25.6% vs 12.8%），意味着1/4晚期ESCC患者生存期超过3年，且不受患者PD-L1 TPS表达水平影响。该数据刷新了晚期食管癌一线治疗研究3年OS率纪录4-7，为晚期食管癌实现临床治愈的目标奠定了坚实基础，也为医生和患者临床治疗提供了宝贵的参考。公司PD-1抑制剂不断精进，从晚期食管癌开始已经逐步推进到局部晚期不可切和可手术切除的治疗，逐步积累证据，并且持续探索全新的治疗组合，力争打破食管癌治疗的困境，为食管癌的临床诊疗带来更多选择。未来，公司将一如既往秉持以患者为中心的理念，努力研制更多新药、好药，惠及更多食管癌患者。参考文献 1.广东疾控:https://mp.weixin.qq.com/s/XjzopJEgxMuLnjCP5jHvCw 2.科普中国:https://mp.weixin.gq.com/s/nDzlJzpkUsVXPU4CGFYO-Q 3.中国医学科学院肿瘤医院胸外科:https://mp.weixin.qq.com/s/x9i6g6b-RAl8qEieepcrBw 4. Huiyan Luo, et al. Final analysis of the randomized phase 3 ESCORT-1st trial: Camrelizumab plus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma. 2024 ASCO Abstract 4055. 5. Harry H. Yoon, et al. Global, randomized, phase III study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced/metastatic esophageal squamous cell carcinoma (RATIONALE-306 update): Minimum 3-year survival follow-up. 2024 ASCO Abstract 4032. 6. Ian Chau, et al. Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): 45-month (mo) follow-up from CheckMate 648. 2024 ASCO Abstract 4034. 7. Manish A. Shah, et al. First-line pembrolizumab (pembro) plus chemotherapy (chemo) for advanced esophageal cancer: 5-year outcomes from the phase 3 KEYNOTE-590 study. 2024 ASCO Abstract 250 内容：恒瑞 on call 排版：程梦真责编：王玲往期精选 | 研发创新 | 恒瑞医药新突破！中国首个自研阿片类镇痛创新药富马酸泰吉利定获批上市代谢领域再下一城！恒瑞医药糖尿病创新药瑞格列汀（瑞泽唐®）获批 | 国际化 | 海外BD再传捷报！恒瑞医药GLP-1类创新药组合实现海外许可恒瑞医药与默克达成合作，携手推进癌症创新疗法 | 重磅奖项 | 喜报！恒瑞医药荣获2023年度国家科技进步奖恒瑞医药连续六年入选全球制药企业50强榜单！ | 社会公益 | “健康中国行·重走长征路”项目启动仪式圆满举行！恒瑞提供公益支持，助力健康中国恒瑞医药集团向中国扶贫基金会捐赠3000万设立“健康帮扶基金”

ASCO会议